[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

RS60827B1 - Postupci lečenja plućnih netuberkuloznih mikobakterijskih infekcija - Google Patents

Postupci lečenja plućnih netuberkuloznih mikobakterijskih infekcija

Info

Publication number
RS60827B1
RS60827B1 RS20201143A RSP20201143A RS60827B1 RS 60827 B1 RS60827 B1 RS 60827B1 RS 20201143 A RS20201143 A RS 20201143A RS P20201143 A RSP20201143 A RS P20201143A RS 60827 B1 RS60827 B1 RS 60827B1
Authority
RS
Serbia
Prior art keywords
methods
treating pulmonary
mycobacterial infections
tuberculous mycobacterial
pulmonary non
Prior art date
Application number
RS20201143A
Other languages
English (en)
Inventor
Gina Eagle
Renu Gupta
Original Assignee
Insmed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insmed Inc filed Critical Insmed Inc
Publication of RS60827B1 publication Critical patent/RS60827B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
RS20201143A 2014-05-15 2015-05-15 Postupci lečenja plućnih netuberkuloznih mikobakterijskih infekcija RS60827B1 (sr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461993439P 2014-05-15 2014-05-15
US201462042126P 2014-08-26 2014-08-26
US201462048068P 2014-09-09 2014-09-09
US201462056296P 2014-09-26 2014-09-26
EP18203799.4A EP3466432B1 (en) 2014-05-15 2015-05-15 Methods for treating pulmonary non-tuberculous mycobacterial infections

Publications (1)

Publication Number Publication Date
RS60827B1 true RS60827B1 (sr) 2020-10-30

Family

ID=54480776

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20201143A RS60827B1 (sr) 2014-05-15 2015-05-15 Postupci lečenja plućnih netuberkuloznih mikobakterijskih infekcija

Country Status (22)

Country Link
US (14) US10238675B2 (sr)
EP (5) EP3466432B1 (sr)
JP (4) JP6646653B2 (sr)
KR (4) KR102447412B1 (sr)
CN (1) CN106535877A (sr)
AU (2) AU2015258947B2 (sr)
BR (1) BR112016026699B1 (sr)
CA (1) CA2949078C (sr)
CY (2) CY1122129T1 (sr)
DK (2) DK3142643T3 (sr)
ES (4) ES2981634T3 (sr)
HR (1) HRP20191805T1 (sr)
HU (1) HUE051440T2 (sr)
LT (2) LT3142643T (sr)
ME (1) ME03536B (sr)
MX (2) MX2016014921A (sr)
NZ (1) NZ726256A (sr)
PL (2) PL3466432T3 (sr)
PT (2) PT3142643T (sr)
RS (1) RS60827B1 (sr)
SI (2) SI3466432T1 (sr)
WO (1) WO2015175939A1 (sr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029994T2 (en) 2005-12-08 2017-04-28 Insmed Inc Lipid-based preparations of antinfectants for the treatment of lung infections
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
AU2013352259B2 (en) 2012-11-29 2018-06-14 Insmed Incorporated Stabilized vancomycin formulations
NO2699580T3 (sr) 2014-01-24 2018-02-24
RS60827B1 (sr) 2014-05-15 2020-10-30 Insmed Inc Postupci lečenja plućnih netuberkuloznih mikobakterijskih infekcija
WO2018022978A1 (en) * 2016-07-29 2018-02-01 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating bronchiectasis
WO2018186998A1 (en) * 2017-04-05 2018-10-11 Aradigm Corporation Liposomal anti-infective formulations to inhibit non-tuberculous mycobacteria (ntm) microaggregate formation and establishment of ntm biofilm
US11938169B2 (en) 2017-10-16 2024-03-26 Drugrecure Aps GM-CSF for treating refractory non-tuberculous mycobacteria infections
CN108310393A (zh) * 2018-02-12 2018-07-24 丹诺医药(苏州）有限公司 一种利福霉素-喹嗪酮偶联分子的应用
CN118416078A (zh) 2018-03-01 2024-08-02 阿斯利康(瑞典)有限公司 药物组合物
US11571386B2 (en) 2018-03-30 2023-02-07 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
US10736847B2 (en) 2018-07-03 2020-08-11 Becton, Dickinson And Company Inverting device for liposome preparation by centrifugation
WO2020018547A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
US20220081470A1 (en) * 2019-01-05 2022-03-17 Foundation For Neglected Disease Research Thiazolyl peptides for the treatment nontuberculous mycobacterial infections
CA3157104A1 (en) * 2019-11-06 2021-05-14 Thomas Hofmann Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods of treatment comprising them
KR102275997B1 (ko) * 2019-11-07 2021-07-13 연세대학교 산학협력단 숙주지향치료를 위한 조성물
US11808135B2 (en) 2020-01-16 2023-11-07 Halliburton Energy Services, Inc. Systems and methods to perform a downhole inspection in real-time
US20240009202A1 (en) * 2020-08-19 2024-01-11 Mitoimmune Therapeutics Inc. Mitochondria-targeted antioxidant as agent for treating pathologic inflammation caused by mabc-r infection
JP2023538853A (ja) * 2020-08-31 2023-09-12 インスメッド インコーポレイテッド 新たに診断されたマイコバクテリウム・アビウム・コンプレックス肺感染症の処置方法
EP4313066A1 (en) * 2021-03-24 2024-02-07 Insmed Incorporated Combination therapy for treating non-tuberculous mycobacterial lung disease
US20240139148A1 (en) * 2021-06-11 2024-05-02 Colorado State University Research Foundation Compositions and methods for treating non-tuberculous mycobacterial infections
KR102613631B1 (ko) * 2021-11-05 2023-12-15 연세대학교 산학협력단 마이코박테리움 아비움 복합체 감염증의 중증도 예측용 대사체 마커
KR102615869B1 (ko) * 2021-11-05 2023-12-21 연세대학교 산학협력단 마이코박테리움 아비움 복합체 폐질환 환자의 정보에 따른 치료 반응 예측용 지질대사체 마커
KR102596057B1 (ko) * 2021-11-05 2023-11-01 연세대학교 산학협력단 마이코박테리움 아비움 복합체 감염질환 진단용 지질대사체 마커
WO2023080663A1 (ko) * 2021-11-05 2023-05-11 연세대학교 산학협력단 마이코박테리움 아비움 복합체 감염질환 진단 또는 중증도 예측용 대사체 마커
EP4444282A1 (en) * 2021-12-07 2024-10-16 AN2 Therapeutics, Inc. Combinations

Family Cites Families (366)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3006698A (en) 1959-11-25 1961-10-31 Gen Motors Corp Bearing assembly
US3061303A (en) 1961-02-21 1962-10-30 Didde Glaser Inc Self-centering parallel guide assembly
US3091572A (en) 1962-07-16 1963-05-28 Schering Corp Gentamycin and method of production
US3136704A (en) 1962-12-05 1964-06-09 Schering Corp Manufacture of gentamycin
US3852557A (en) 1973-07-12 1974-12-03 Cutler Hammer Inc Electric switch with pivoting and wiping movable contractor
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
GB2046092B (en) 1979-03-05 1983-11-02 Toyama Chemical Co Ltd Pharmaceutical composition containing a lysophospholid and a phospholipid
HU184141B (en) 1979-12-27 1984-07-30 Human Oltoanyagtermelo Adjuvant particles compositions containing said particles and biologically active substances adsorbed thereon and a process for the preparation thereof
US4451447A (en) 1980-03-31 1984-05-29 Bristol-Myers Company Pharmaceutical formulations
EP0069307B1 (de) 1981-07-02 1986-03-05 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Verfahren zur Herstellung von Liposomenlösungen
US4547490A (en) 1981-12-31 1985-10-15 Neomed, Inc. Synthetic whole blood and a method of making the same
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4684625A (en) 1982-07-08 1987-08-04 Syntex (U.S.A.) Inc. Method for enhancing the anti-infective activity of muramyldipeptide derivatives
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US5169637A (en) 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
US4981692A (en) 1983-03-24 1991-01-01 The Liposome Company, Inc. Therapeutic treatment by intramammary infusion
US5030453A (en) 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
US4515736A (en) 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
US5059591B1 (en) 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
CA1237670A (en) 1983-05-26 1988-06-07 Andrew S. Janoff Drug preparations of reduced toxicity
US4606939A (en) 1983-06-22 1986-08-19 The Ohio State University Research Foundation Small particle formation
CA1237671A (en) 1983-08-01 1988-06-07 Michael W. Fountain Enhancement of pharmaceutical activity
GB8322178D0 (en) 1983-08-17 1983-09-21 Sterwin Ag Preparing aerosol compositions
EP0153955A1 (en) 1983-09-06 1985-09-11 Health Research, Inc. Liposome delivery method for decreasing the toxicity of an antitumor drug
US4721612A (en) 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4794000A (en) 1987-01-08 1988-12-27 Synthetic Blood Corporation Coacervate-based oral delivery system for medically useful compositions
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
SE8403905D0 (sv) 1984-07-30 1984-07-30 Draco Ab Liposomes and steroid esters
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
AU587472B2 (en) 1985-05-22 1989-08-17 Liposome Technology, Inc. Liposome inhalation method and system
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US5409704A (en) 1985-06-26 1995-04-25 The Liposome Company, Inc. Liposomes comprising aminoglycoside phosphates and methods of production and use
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
DE3689769T2 (de) 1985-07-05 1994-07-21 Liposome Co Inc Multilamellare liposome mit verbesserter einschliessungswirkung.
JPH0665648B2 (ja) 1985-09-25 1994-08-24 塩野義製薬株式会社 白金系抗癌物質の安定な凍結真空乾燥製剤
US5041278A (en) 1985-10-15 1991-08-20 The Liposome Company, Inc. Alpha tocopherol-based vesicles
US4861580A (en) 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
US5041581A (en) 1985-10-18 1991-08-20 The University Of Texas System Board Of Regents Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US5023087A (en) 1986-02-10 1991-06-11 Liposome Technology, Inc. Efficient method for preparation of prolonged release liposome-based drug delivery system
US6759057B1 (en) 1986-06-12 2004-07-06 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
US4833134A (en) 1986-08-19 1989-05-23 Takeda Chemical Industries, Ltd. Cephem compounds
US5049388A (en) 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US4933121A (en) 1986-12-10 1990-06-12 Ciba Corning Diagnostics Corp. Process for forming liposomes
US5320906A (en) 1986-12-15 1994-06-14 Vestar, Inc. Delivery vehicles with amphiphile-associated active ingredient
IL97538A (en) 1986-12-23 1995-03-15 Liposome Co Inc Multilayer liposomes containing guanidino aminoglycosides and their preparation
US5723147A (en) 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
US5616334A (en) 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
ATE113468T1 (de) 1987-07-29 1994-11-15 Liposome Co Inc Verfahren zur trennung von teilchen nach grösse.
US4857311A (en) 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
US4895452A (en) 1988-03-03 1990-01-23 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
MX9203504A (es) 1988-04-20 1992-07-01 Liposome Co Inc Complejo agente: lipido activo de alta proporcion.
US5269979A (en) 1988-06-08 1993-12-14 Fountain Pharmaceuticals, Inc. Method for making solvent dilution microcarriers
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
BE1001869A3 (fr) 1988-10-12 1990-04-03 Franz Legros Procede d'encapsulation liposomiale d'antibiotiques aminoglucosidiques, en particulier de la gentamycine.
US4952405A (en) * 1988-10-20 1990-08-28 Liposome Technology, Inc. Method of treating M. avium infection
US4906476A (en) 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5006343A (en) 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US5843473A (en) 1989-10-20 1998-12-01 Sequus Pharmaceuticals, Inc. Method of treatment of infected tissues
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
WO1991009616A1 (en) 1989-12-22 1991-07-11 Yale University Quinolone antibiotics encapsulated in lipid vesicles
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5820848A (en) 1990-01-12 1998-10-13 The Liposome Company, Inc. Methods of preparing interdigitation-fusion liposomes and gels which encapsulate a bioactive agent
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7908791A (en) 1990-05-08 1991-11-27 Liposome Technology, Inc. Direct spray-dried drug/lipid powder composition
US6623671B2 (en) 1990-10-05 2003-09-23 Royden M. Coe Liposome extrusion process
US5614216A (en) 1990-10-17 1997-03-25 The Liposome Company, Inc. Synthetic lung surfactant
IT1245761B (it) 1991-01-30 1994-10-14 Alfa Wassermann Spa Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
ATE132367T1 (de) 1991-02-14 1996-01-15 Baxter Int Bindung substratspezifischer affinitätssubstanzen an liposomen
US5228346A (en) 1991-04-08 1993-07-20 Marathon Oil Company Method of determining gas flow volume
US6629646B1 (en) 1991-04-24 2003-10-07 Aerogen, Inc. Droplet ejector with oscillating tapered aperture
DE59108798D1 (de) 1991-11-07 1997-08-28 Ritzau Pari Werk Gmbh Paul Vernebler insbesondere zur Anwendung in Geräten für die Inhalationstherapie
US5770563A (en) 1991-12-06 1998-06-23 The United States Of America As Represented By The Department Of Health And Human Services Heparin- and sulfatide binding peptides from the type I repeats of human thrombospondin and conjugates thereof
AU3467193A (en) 1991-12-17 1993-07-19 Regents Of The University Of California, The Gene therapy for cystic fibrosis transmembrane conductance regulator activity (CFTR)
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US6890555B1 (en) 1992-02-05 2005-05-10 Qlt, Inc. Liposome compositions of porphyrin photosensitizers
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5871710A (en) 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
AU3244393A (en) 1992-12-02 1994-06-22 Vestar, Inc. Antibiotic formulation and process
US5958449A (en) 1992-12-02 1999-09-28 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for bacterial infections
US5665383A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
ZA938381B (en) 1993-03-22 1994-06-13 Inland Steel Co Apparatus and method for magnetically confining molten metal using concentrating fins
CA2120197A1 (en) 1993-04-02 1994-10-03 Kenji Endo Stable aqueous dispersions containing liposomes
EP0692961A1 (en) 1993-04-02 1996-01-24 The Liposome Company, Inc. Method of producing liposomes
US5759571A (en) 1993-05-11 1998-06-02 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for drug resistant infections
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
JPH06345663A (ja) 1993-06-08 1994-12-20 Sumitomo Pharmaceut Co Ltd バンコマイシン含有リポソーム製剤
DE69426884T2 (de) 1993-07-08 2001-06-21 The Liposome Co.,Inc. Verfahren zum kontrollieren der liposomengrösse
CA2101241C (en) 1993-07-23 1998-12-22 Jonathan P. Wong Liposome-encapsulated ciprofloxacin
AU683957B2 (en) 1993-11-05 1997-11-27 Amgen, Inc. Liposome preparation and material encapsulation method
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
EP0741580A4 (en) 1993-12-14 2001-07-11 Univ Johns Hopkins Med CONTROLLED RELEASE OF PHARMACEUTICALLY ACTIVE SUBSTANCES FOR IMMUNOTHERAPY
DE59308788D1 (de) 1993-12-17 1998-08-20 Pari Gmbh Zerstäuberdüse
WO1995024929A2 (en) 1994-03-15 1995-09-21 Brown University Research Foundation Polymeric gene delivery system
US5610198A (en) 1994-03-18 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services Anti-mycobacterial compositions and their use for the treatment of tuberculosis and related diseases
EP0682955B1 (de) 1994-05-19 2001-09-05 PARI GmbH Spezialisten für effektive Inhalation Vorrichtung zur Trocknung und Pufferung von Aerosolen
US5550109A (en) 1994-05-24 1996-08-27 Magainin Pharmaceuticals Inc. Inducible defensin peptide from mammalian epithelia
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5993850A (en) 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US6000394A (en) 1994-10-26 1999-12-14 Paul Rizau Pari-Werk Gmbh Generation of an aerosol of an exact dose
SA95160463B1 (ar) 1994-12-22 2005-10-04 استرا أكتيبولاج مساحيق للاستنشاق
US5662929A (en) 1994-12-23 1997-09-02 Universite De Montreal Therapeutic liposomal formulation
US5883074A (en) 1995-02-08 1999-03-16 Microcide Pharmaceuticals, Inc. Potentiators of antibacterial agents
US5972379A (en) 1995-02-14 1999-10-26 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering a quinolone
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
EP0825852B1 (en) 1995-04-18 2004-07-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
US5855610A (en) 1995-05-19 1999-01-05 Children's Medical Center Corporation Engineering of strong, pliable tissues
EP0833613A1 (en) 1995-05-26 1998-04-08 Somatix Therapy Corporation Delivery vehicles comprising stable lipid/nucleic acid complexes
WO1996039146A1 (en) 1995-06-06 1996-12-12 Bayer Corporation Non-irritation, non-sensitizing, non-ototoxic otic antibacterial compositions
DE19520622C2 (de) 1995-06-06 2003-05-15 Pari Gmbh Vorrichtung zum Vernebeln von Fluiden
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
JPH11507697A (ja) 1995-06-09 1999-07-06 エヌ． ドロハン，ウィリアム キチンヒドロゲル、それらの製造方法及び利用
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
WO1997014740A1 (en) 1995-10-19 1997-04-24 Receptagen Corporation Discrete-length polyethylene glycols
DE19602628C2 (de) 1996-01-25 2000-06-29 Pari Gmbh Vernebler
GB9602969D0 (en) 1996-02-13 1996-04-10 The Technology Partnership Plc Liquid supply apparatus
US5840702A (en) 1996-03-22 1998-11-24 Uab Research Foundation Cystic fibrosis treatment
AU733212B2 (en) 1996-03-28 2001-05-10 Board Of Trustees Of The University Of Illinois, The Material and methods for making improved liposome compositions
US5875776A (en) 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US6132765A (en) 1996-04-12 2000-10-17 Uroteq Inc. Drug delivery via therapeutic hydrogels
CA2174803C (en) 1996-04-23 2000-07-11 Jonathan P. Wong Use of liposome encapsulated ciprofloxacin as an immunotherapeutic drug
DE19616573C2 (de) 1996-04-25 1999-03-04 Pari Gmbh Verwendung unterkritischer Treibmittelmischungen und Aerosole für die Mikronisierung von Arzneimitteln mit Hilfe dichter Gase
EP0910382B1 (en) 1996-04-26 2003-06-11 Magainin Pharmaceuticals Inc. Squalamine in combination with other anti-cancer agents for treating tumors
GB9609779D0 (en) 1996-05-10 1996-07-17 Univ Bruxelles Freeze dried liposome encapsulated amphiphilic drug compositions and a process for the preparation thereof
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6770291B2 (en) 1996-08-30 2004-08-03 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
US6503881B2 (en) 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
AU714992B2 (en) 1996-08-23 2000-01-13 Alza Corporation Liposomes containing a cisplatin compound
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
TW520297B (en) 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US6451784B1 (en) 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
CA2275889C (en) 1996-12-30 2008-03-18 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
DE19713636A1 (de) 1997-04-02 1998-10-08 Pari Gmbh Atemzugsimulator
US20020039594A1 (en) 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
US5957339A (en) 1997-06-23 1999-09-28 Keystone Manufacturing Co., Inc. Water filtration system
JP4142149B2 (ja) 1997-07-10 2008-08-27 明治製菓株式会社 バンコマイシンの凍結乾燥製剤
DE19734022C2 (de) 1997-08-06 2000-06-21 Pari Gmbh Inhalationstherapiegerät mit einem Ventil zur Begrenzung des Inspirationsflusses
US6106858A (en) 1997-09-08 2000-08-22 Skyepharma, Inc. Modulation of drug loading in multivescular liposomes
CA2215716C (en) 1997-09-17 1999-12-07 Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence Aerosol delivery of liposome-encapsulated fluoroquinolone
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
EP1024814B1 (en) 1997-10-22 2007-08-29 Jens Ponikau Use of antifungal agents for the topical treatment of fungus-induced mucositis
WO1999025319A1 (en) 1997-11-14 1999-05-27 Depotech Corporation Production of multivesicular liposomes
US6051251A (en) 1997-11-20 2000-04-18 Alza Corporation Liposome loading method using a boronic acid compound
AU1656799A (en) 1997-12-12 1999-07-05 Inex Pharmaceuticals Corp. Cationic drugs encapsulated in anionic liposomes
GB9827370D0 (en) 1998-01-16 1999-02-03 Pari Gmbh Mouthpiece for inhalation therapy units
US6468532B1 (en) 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
HUP0102892A3 (en) 1998-05-27 2002-12-28 Euro Celtique Sa Drug delivery system comprising a tightly compacted solid medicament stock, process for its preparation and for its use
DE19827228C2 (de) 1998-06-18 2000-07-13 Pari Gmbh Flüssigkeitszerstäubervorrichtung
US6200598B1 (en) 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
US6916490B1 (en) 1998-07-23 2005-07-12 UAB Research Center Controlled release of bioactive substances
US6162462A (en) 1998-08-12 2000-12-19 New York University Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient
DE19846382C1 (de) 1998-10-08 2000-07-06 Pari Gmbh Zählwerk und seine Verwendung in Inhalatoren, Verneblern oder ähnlichen Dosieraerosolvorrichtungen
ES2281199T3 (es) 1998-11-12 2007-09-16 Transave, Inc. Sistema de inhalacion.
US6534018B1 (en) 1998-11-13 2003-03-18 Optime Therapeutics, Inc. Method and apparatus for liposome production
US6855296B1 (en) 1998-11-13 2005-02-15 Optime Therapeutics, Inc. Method and apparatus for liposome production
SI20959A (sl) 1998-12-17 2003-02-28 Pathogenesis Corporation Metoda za zdravljenje hudega kroničnega bronhitisa (bronhiektazije) z aerosoliziranimi antibiotiki
US6211162B1 (en) 1998-12-30 2001-04-03 Oligos Etc. Inc. Pulmonary delivery of protonated/acidified nucleic acids
EP1150658B1 (en) 1999-02-08 2004-08-04 Alza Corporation Method for controlling liposome size
US6518243B1 (en) 1999-04-02 2003-02-11 Trustees Of Princeton University Desleucyl glycopeptide antibiotics and methods of making same
US6613352B2 (en) 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
US7297344B1 (en) 1999-05-27 2007-11-20 Euro-Celtique, S.A. Preparations for the promotion of wound healing in the upper respiratory tract and/or ear
WO2000074634A2 (en) 1999-06-03 2000-12-14 Au Jessie L S Methods and compositions for modulating cell proliferation and cell death
AU780194B2 (en) 1999-06-24 2005-03-10 Kyowa Hakko Kirin Co., Ltd. Method of regulating leakage of drug encapsulated in liposomes
IL147089A0 (en) 1999-07-15 2002-08-14 Inex Pharmaceuticals Corp Methods of preparing lipid-encapsulated therapeutic agents
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6174878B1 (en) 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
US6235177B1 (en) 1999-09-09 2001-05-22 Aerogen, Inc. Method for the construction of an aperture plate for dispensing liquid droplets
DE19953317C1 (de) 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
JP4198850B2 (ja) 1999-11-29 2008-12-17 オムロンヘルスケア株式会社 液体噴霧装置
IL150027A0 (en) 1999-12-04 2002-12-01 Res Dev Foundation Carbon dioxide enhancement of inhalation therapy
DE10004465A1 (de) 2000-02-02 2001-08-16 Pari Gmbh Inhalationsvernebler
ATE341310T1 (de) 2000-02-04 2006-10-15 Lipoxen Technologies Ltd Dehydratisierungs-/rehydratisierungsverfahren zur herstellung von liposome
US6761877B2 (en) 2000-02-18 2004-07-13 Biocrystal, Ltd. Functionalized encapsulated fluorescent nanocrystals
US7758888B2 (en) 2000-04-21 2010-07-20 Sol-Gel Technologies Ltd. Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
US6948491B2 (en) 2001-03-20 2005-09-27 Aerogen, Inc. Convertible fluid feed system with comformable reservoir and methods
US7100600B2 (en) 2001-03-20 2006-09-05 Aerogen, Inc. Fluid filled ampoules and methods for their use in aerosolizers
US6968840B2 (en) 2000-05-05 2005-11-29 Aerogen, Inc. Methods and systems for operating an aerosol generator
US7971588B2 (en) 2000-05-05 2011-07-05 Novartis Ag Methods and systems for operating an aerosol generator
US7600511B2 (en) 2001-11-01 2009-10-13 Novartis Pharma Ag Apparatus and methods for delivery of medicament to a respiratory system
US8336545B2 (en) 2000-05-05 2012-12-25 Novartis Pharma Ag Methods and systems for operating an aerosol generator
MXPA02010884A (es) 2000-05-05 2003-03-27 Aerogen Ireland Ltd Aparato y metodo para el suministro de medicamentos al sistema respiratorio.
WO2001093846A2 (en) 2000-05-23 2001-12-13 The Trustees Of Columbia University In The City Of New York Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of clycosaminoglycans
US6338859B1 (en) 2000-06-29 2002-01-15 Labopharm Inc. Polymeric micelle compositions
US6521736B2 (en) 2000-09-15 2003-02-18 University Of Massachusetts Amphiphilic polymeric materials
HUP0303719A2 (hu) 2000-10-16 2004-03-01 Neopharm, Inc. Mitoxantron hatóanyag-tartalmú liposzómás gyógyszerkészítmények és eljárás az előállításukra
CN1116875C (zh) 2000-10-19 2003-08-06 南京振中生物工程有限公司 紫杉醇脂质组合物及其制备方法
US6497901B1 (en) 2000-11-02 2002-12-24 Royer Biomedical, Inc. Resorbable matrices for delivery of bioactive compounds
EP1203614A1 (de) 2000-11-03 2002-05-08 Polymun Scientific Immunbiologische Forschung GmbH Verfahren und Vorrichtung zur Herstellung von Lipidvesikeln
AU2002219998B2 (en) 2000-12-01 2006-03-02 Biomira, Inc. Preparation of large liposomes by infusion into peg
DE10102846B4 (de) 2001-01-23 2012-04-12 Pari Pharma Gmbh Aerosolgenerator
CA2437555A1 (en) 2001-02-01 2002-08-08 Yiyu Zou Stabilised polymeric aerosols for pulmonary gene delivery
DE10109897A1 (de) 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
US6546927B2 (en) 2001-03-13 2003-04-15 Aerogen, Inc. Methods and apparatus for controlling piezoelectric vibration
JP2002318193A (ja) 2001-04-24 2002-10-31 Canon Inc ネブライザ及び高周波誘導結合プラズマ発光分析装置
US6554201B2 (en) 2001-05-02 2003-04-29 Aerogen, Inc. Insert molded aerosol generator and methods
US6732944B2 (en) 2001-05-02 2004-05-11 Aerogen, Inc. Base isolated nebulizing device and methods
DE60210402T2 (de) 2001-05-18 2006-12-07 Chiron Corp., Emeryville System zur Abgabe einer Tobramycin-Formulierung
US20030060451A1 (en) 2001-05-29 2003-03-27 Rajneesh Taneja Enhancement of oral bioavailability of non-emulsified formulations of prodrug esters with lecithin
DE10126807C2 (de) 2001-06-01 2003-12-04 Pari Gmbh Inhalationstherapiegerät mit einem Ventil zur Begrenzung des Inspirationsflusses
DE10126808C1 (de) 2001-06-01 2002-08-14 Pari Gmbh Inhalationsmaske
EP1269993A1 (en) 2001-06-21 2003-01-02 Applied NanoSystems B.V. Delivery of small hydrophilic molecules packaged into lipid vesicles
WO2003000236A1 (en) 2001-06-23 2003-01-03 Lyotropic Therapeutics, Inc Particles with improved solubilization capacity
AU2002323151A1 (en) 2001-08-13 2003-03-03 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
WO2003015707A2 (en) 2001-08-20 2003-02-27 Transave, Inc. Method for treating lung cancers
US6623723B2 (en) 2001-08-21 2003-09-23 Cellular Sciences Inc. Method for treating bronchial constriction and bronchospasm
WO2003018031A2 (en) * 2001-08-21 2003-03-06 Pfizer Products Inc. Single dose azithromycin for treating respiratory infections
EP1304130B1 (de) 2001-10-18 2004-06-23 PARI GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
DE50106644D1 (de) 2001-10-18 2005-08-04 Pari Gmbh Inhalationstherapievorrichtung
WO2003035876A1 (de) 2001-10-26 2003-05-01 Ribopharma Ag Verwendung einer doppelsträngigen ribonukleinsäure zur behandlung einer infektion mit einem (+)-strang-rna-virus
US20030096774A1 (en) 2001-11-21 2003-05-22 Igor Gonda Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same
WO2003053411A1 (en) 2001-12-19 2003-07-03 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US6845770B2 (en) 2002-01-15 2005-01-25 Aerogen, Inc. Systems and methods for clearing aerosols from the effective anatomic dead space
WO2003075889A1 (en) 2002-03-05 2003-09-18 Transave, Inc. An inhalation system for prevention and treatment of intracellular infections
US20030205226A1 (en) 2002-05-02 2003-11-06 Pre Holding, Inc. Aerosol medication inhalation system
AU2003256253A1 (en) 2002-05-20 2003-12-02 Aerogen, Inc. Aerosol for medical treatment and methods
AU2003245160B2 (en) 2002-06-28 2009-09-24 Arbutus Biopharma Corporation Method and apparatus for producing liposomes
CA2494673A1 (en) 2002-08-02 2004-07-01 Transave, Inc. Platinum aggregates and process for producing the same
EP1386672B1 (en) 2002-08-02 2010-04-07 PARI Pharma GmbH Fluid droplet production apparatus
AU2003268087A1 (en) 2002-08-23 2004-03-11 Ian Ma Liposomal gemcitabine compositions for better drug delivery
DE10239321B3 (de) 2002-08-27 2004-04-08 Pari GmbH Spezialisten für effektive Inhalation Aerosoltherapievorrichtung
KR100489701B1 (ko) 2002-10-09 2005-05-16 주식회사 태평양 고농도의 트리터페노이드를 함유하는 미소화 리포좀 및 그제조방법
US20230008563A1 (en) 2002-10-29 2023-01-12 Insmed Incorporated Sustained release of antiinfectives
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US7879351B2 (en) 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
MXPA05004580A (es) 2002-10-29 2005-07-26 Transave Inc Liberacion sostenida de anti - infecciosos.
DE10250625A1 (de) 2002-10-30 2004-05-19 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
CN100367932C (zh) 2002-11-26 2008-02-13 吉里德科学公司 借助梯度的脂质体中药物装填的方法
DE10257381B4 (de) 2002-12-09 2006-09-14 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
KR20050105455A (ko) 2003-02-11 2005-11-04 네오팜 인코포레이티드 리포좀 제제의 제조 방법
WO2004076695A1 (en) 2003-02-24 2004-09-10 Gtc Biotherapeutics, Inc. Methods of tangential flow filtration and an apparatus therefore
US7968115B2 (en) 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
SI2368553T1 (sl) 2003-04-08 2015-05-29 Progenics Pharmaceuticals, Inc. Farmacevtske formulacije, vsebujoče metilnatrekson
US6900184B2 (en) 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection
DE10320143A1 (de) 2003-05-06 2004-12-16 Pari GmbH Spezialisten für effektive Inhalation Vernebleranschlussvorrichtung für Beatmungsgeräte oder dergleichen
DE10322505B4 (de) 2003-05-19 2009-11-05 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapiemaske und -vorrichtung für Tiere
US8058493B2 (en) 2003-05-21 2011-11-15 Baker Hughes Incorporated Removing amines from hydrocarbon streams
CA2527625A1 (en) 2003-05-30 2004-12-23 Alza Corporation Method of pulmonary administration of an agent
US8616195B2 (en) 2003-07-18 2013-12-31 Novartis Ag Nebuliser for the production of aerosolized medication
CA2536071A1 (en) 2003-08-20 2005-03-03 Locomogene, Inc. Methods for detecting regulatory effect on synoviolin activity
GB2388581A (en) 2003-08-22 2003-11-19 Danisco Coated aqueous beads
DE10345950A1 (de) 2003-10-02 2005-05-19 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung mit Ventil
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
DE10348237A1 (de) 2003-10-16 2005-05-19 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung mit einem Düsenvernebler
US20050214224A1 (en) 2003-11-04 2005-09-29 Nektar Therapeutics Lipid formulations for spontaneous drug encapsulation
CN1913917B (zh) 2003-12-31 2012-02-01 正统逻辑公司 凝血酶肽衍生物的药物组合物
US7452524B2 (en) 2004-01-27 2008-11-18 Gilead Sciences, Inc. Method for improvement of tolerance for therapeutically effective agents delivered by inhalation
US7556799B2 (en) 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
DE102004016985B4 (de) 2004-04-07 2010-07-22 Pari Pharma Gmbh Aerosolerzeugungsvorrichtung und Inhalationsvorrichtung
JP4452799B2 (ja) 2004-07-14 2010-04-21 独立行政法人産業技術総合研究所 コアセルベートを活用したリポソームの製造方法
JP2008518951A (ja) 2004-10-28 2008-06-05 アルザ コーポレイション 凍結乾燥リポソーム配合物及び方法
CA2587411A1 (en) 2004-11-17 2006-05-26 Protiva Biotherapeutics, Inc. Sirna silencing of apolipoprotein b
US8337815B2 (en) 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
DE102005006374B3 (de) 2005-02-11 2006-07-20 Pari GmbH Spezialisten für effektive Inhalation Aerosolerzeugungsvorrichtung und Inhalationstherapiegerät mit einer derartigen Vorrichtung
DE102005006372B4 (de) 2005-02-11 2007-11-29 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung und Verfahren zu deren Betrieb
DE102005006375B4 (de) 2005-02-11 2007-10-11 Pari GmbH Spezialisten für effektive Inhalation Aerosolerzeugungsvorrichtung für Inhalationstherapiegeräte
US20060198940A1 (en) 2005-03-04 2006-09-07 Mcmorrow David Method of producing particles utilizing a vibrating mesh nebulizer for coating a medical appliance, a system for producing particles, and a medical appliance
JP2006263054A (ja) 2005-03-23 2006-10-05 Konica Minolta Sensing Inc 呼吸器系疾患関連解析データの取得方法、オキシメータシステム及びその動作プログラム、オキシメータ並びに酸素補給システム
EP1712220A1 (en) 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Pharmaceutical aerosol composition
WO2006127181A2 (en) 2005-05-25 2006-11-30 Aerogen, Inc. Vibration systems and methods
DE102005024779B4 (de) 2005-05-31 2008-02-21 Pari GmbH Spezialisten für effektive Inhalation Atemzuggesteuerte Inhalationstherapievorrichtung
DE102005029498B4 (de) 2005-06-24 2007-08-30 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
USD656604S1 (en) 2005-06-28 2012-03-27 Pari Gmbh Part for inhalation therapy nebuliser
DE102005034403B3 (de) 2005-07-22 2007-02-22 Airbus Deutschland Gmbh Führungsmittel für eine Vorrichtung zur Herstellung von Faservorformlingen im TFP-Verfahren für Verbundbauteile
JP5639338B2 (ja) 2005-07-27 2014-12-10 プロチバ バイオセラピューティクス インコーポレイティッド リポソームの製造システムおよび製造方法
WO2007026489A1 (ja) 2005-08-31 2007-03-08 Toray Industries, Inc. ポリ乳酸系樹脂積層シートおよびその成形体
DE602006008637D1 (de) 2005-09-07 2009-10-01 Philips Intellectual Property System und verfahren zum induktiven messen der bioimpedanz eines leitfähigen gewebes
US20070065367A1 (en) 2005-09-20 2007-03-22 Rany Condos Method of treating pulmonary disease with interferons
KR100705981B1 (ko) 2005-10-12 2007-04-10 주식회사 리제론 인간 성장호르몬을 포함하는 탈모방지 또는 발모촉진용조성물
US20070105758A1 (en) 2005-10-31 2007-05-10 May Thomas B Vancomycin formulations having reduced amount of histamine
DE102006051512A1 (de) 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin
HUE029994T2 (en) 2005-12-08 2017-04-28 Insmed Inc Lipid-based preparations of antinfectants for the treatment of lung infections
DE102006001113B3 (de) 2006-01-09 2007-06-28 Pari GmbH Spezialisten für effektive Inhalation Aerosoltherapievorrichtung
US8263645B2 (en) 2006-02-03 2012-09-11 Pari Pharma Gmbh Disodium cromoglycate compositions and methods for administering same
DE102006006183A1 (de) 2006-02-10 2007-08-16 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung für die Anwendung bei Frühgeborenen und Kleinkindern
US7958887B2 (en) 2006-03-10 2011-06-14 Aradigm Corporation Nozzle pore configuration for intrapulmonary delivery of aerosolized formulations
DE102006012174A1 (de) 2006-03-16 2007-09-20 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapiegerätekompressor
WO2007117550A2 (en) 2006-04-06 2007-10-18 Transave, Inc. Methods for coacervation induced liposomal encapsulation and formulations thereof
DE102006017002B3 (de) 2006-04-11 2007-01-11 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung mit mehrfachen Düsen
USD583928S1 (en) 2006-04-27 2008-12-30 Pari Pharama Gmbh Nebulizer
US20080131497A1 (en) 2006-09-28 2008-06-05 Perkins Walter R Formulations of DNase and Methods of Use Thereof
US8071127B2 (en) 2006-10-24 2011-12-06 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8268347B1 (en) 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8119156B2 (en) 2006-10-24 2012-02-21 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US20080108104A1 (en) * 2006-11-02 2008-05-08 Colorado State University Research Foundation Identification of bacterial species and subspecies using lipids
EP1927373B1 (en) 2006-11-30 2012-08-22 PARI Pharma GmbH Inhalation nebulizer
CN101678033A (zh) * 2007-02-09 2010-03-24 联合治疗公司 用于间质性肺病和哮喘的曲前列尼治疗
EP1980285B1 (de) 2007-04-11 2009-11-18 PARI GmbH Spezialisten für effektive Inhalation Aerosoltherapievorrichtung
WO2008137717A1 (en) 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) * 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) * 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
WO2008137917A1 (en) 2007-05-07 2008-11-13 Transave, Inc. Method of treating bacterial infections with antibacterial formulations
UA27298U (en) 2007-06-13 2007-10-25 Method for preventing pleural empyema after pneumonectomy
UA27804U (en) 2007-07-26 2007-11-12 Method for preventing respiratory complications after surgery in lungs and pleura
EP2030644A1 (en) 2007-08-31 2009-03-04 PARI Pharma GmbH Aerosols for sinunasal drug delivery
NZ562236A (en) 2007-10-05 2010-04-30 Univ Otago Detection of volatile compounds as markers for Mycobacteria tuberculosis
CN101917972A (zh) 2007-10-23 2010-12-15 特兰萨夫公司 脂质体万古霉素制剂
KR101303180B1 (ko) 2007-11-09 2013-09-09 삼성전자주식회사 수직채널 트랜지스터를 구비한 반도체 메모리 소자 및 그제조 방법
DE102007056462B4 (de) 2007-11-23 2011-10-27 Pari Pharma Gmbh Einwegampulle für eine Vorrichtung zur Erzeugung von Aerosolen
US10201587B2 (en) 2008-04-08 2019-02-12 Melinta Therapeutics, Inc. Methods of inhibiting and treating biofilms using glycopeptide antibiotics
DE102008022987A1 (de) 2008-05-09 2009-11-12 Pari Pharma Gmbh Vernebler für Beatmungsmaschinen und Beatmungsmaschine mit einem solchen Vernebler
EP2743265B1 (en) 2008-10-09 2017-03-15 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
AU2010229721A1 (en) 2009-03-26 2011-10-06 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
PL2248517T3 (pl) 2009-05-08 2014-08-29 Pari Pharma Gmbh Stężone formulacje farmaceutyczne stabilizujące komórki tuczne
DE102009026636B4 (de) 2009-06-02 2011-04-14 Pari Pharma Gmbh Verfahren zum Verschweißen einer Membran mit einem Träger bei der Herstellung eines Membranverneblers
ES2614917T3 (es) 2009-07-17 2017-06-02 Nektar Therapeutics Sistemas y métodos para propulsión en nebulizadores sellados
AU2010273955B2 (en) 2009-07-17 2015-08-06 Nektar Therapeutics Negatively biased sealed nebulizers systems and methods
WO2011010260A1 (en) 2009-07-22 2011-01-27 Koninklijke Philips Electronics N.V. Thermal flow sensor integrated circuit with low response time and high sensitivity
US20130034534A1 (en) 2009-09-29 2013-02-07 Philipp Kroneberg Method for treatment of patients with cystic fibrosis
WO2011049960A2 (en) 2009-10-21 2011-04-28 Otonomy, Inc. Compositions and methods for the treatment of sinonasal disorders
US8536220B2 (en) 2010-01-26 2013-09-17 Murray Fulgham Supplement composition and method of use
WO2011108955A1 (en) 2010-03-03 2011-09-09 Universidade De Coimbra Multi -targeting system comprising a nanocarrier, nucleic acid(s) and non-nucleic acid based drug(s)
WO2011133617A1 (en) 2010-04-23 2011-10-27 The Board Of Trustees Of The University Of Illinois Nano-hybrid delivery system for sequential utilization of passive and active targeting
EP3456827A3 (en) 2010-06-02 2019-05-08 Alnylam Pharmaceuticals, Inc. Compositions and methods directed to treating liver fibrosis
KR102012418B1 (ko) 2010-07-12 2019-08-20 셀리아 파마슈티칼즈 에이피에스 에어로졸화에 의한 토브라마이신의 투여에 의한 폐 감염의 치료
CN103179951B (zh) 2010-08-20 2016-01-20 雷迪博士实验室有限公司 磷脂储库
EP2621588A4 (en) 2010-09-27 2014-09-03 Microdose Therapeutx Inc METHODS AND COMPOSITIONS FOR TREATING DISEASE USING INHALATION
EP3470057B1 (en) 2010-09-29 2021-11-03 Pulmatrix Operating Company, Inc. Cationic dry powders comprising magnesium salt
EP2457609A1 (en) 2010-11-24 2012-05-30 PARI Pharma GmbH Aerosol generator
CA2824432C (en) 2011-01-31 2021-10-19 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
SG195038A1 (en) 2011-05-19 2013-12-30 Savara Inc Dry powder vancomycin compositions and associated methods
ES2964682T3 (es) 2011-06-08 2024-04-09 Pari Pharma Gmbh Generador de aerosol
CN107266391B (zh) 2011-10-18 2020-04-17 迪克纳制药公司 胺阳离子脂质及其用途
WO2013086373A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
RU2014130080A (ru) 2011-12-22 2016-02-10 Нуво Рисерч Гмбх Липосомальные композиции хлоритов или хлоратов
US20130280174A1 (en) 2012-04-20 2013-10-24 The Gillette Company Personal care composition comprising metathesized unsaturated polyol esters
US9925295B2 (en) 2012-05-09 2018-03-27 Amedica Corporation Ceramic and/or glass materials and related methods
PT2852391T (pt) 2012-05-21 2022-02-18 Insmed Inc Sistemas para tratamento de infeções pulmonares
WO2014025890A1 (en) * 2012-08-10 2014-02-13 University Of North Texas Health Science Center Drug delivery vehicle comprising conjugates between targeting polyamino acids and fatty acids
CA2925687A1 (en) 2012-09-27 2014-04-03 The University Of North Carolina At Chapel Hill Lipid coated nanoparticles containing agents having low aqueous and lipid solubilities and methods thereof
AU2013352259B2 (en) 2012-11-29 2018-06-14 Insmed Incorporated Stabilized vancomycin formulations
US20160193148A1 (en) 2013-08-01 2016-07-07 University Of Georgia Research Foundation, Inc. Liposomal formulations for the treatment of bacterial infections
US9198359B2 (en) 2013-09-20 2015-12-01 Deere & Company Frame for a reciprocating sieve
WO2015061025A1 (en) 2013-10-22 2015-04-30 Aradigm Corporation Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile
CA2943201A1 (en) 2014-04-08 2015-10-15 Aradigm Corporation Liposomes that form drug nanocrystals after freeze-thaw
US20160120806A1 (en) 2014-04-08 2016-05-05 Aradigm Corporation Nanocrystals formed in a microenvironment
AU2015244275B2 (en) 2014-04-08 2019-08-29 Aradigm Corporation Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria
RS60827B1 (sr) * 2014-05-15 2020-10-30 Insmed Inc Postupci lečenja plućnih netuberkuloznih mikobakterijskih infekcija
SG10201901555UA (en) 2014-08-29 2019-03-28 Emd Millipore Corp Single Pass Tangential Flow Filtration Systems and Tangential Flow Filtration Systems withRecirculation of Retentate
CN107427791B (zh) 2015-03-19 2021-05-14 康涅狄格大学 用于连续制造脂质体药物制剂的系统和方法
EP3319976B1 (en) 2015-07-09 2021-09-01 Insmed Incorporated Compositions and methods for treating lung diseases and lung injury
JP2019500318A (ja) 2015-11-18 2019-01-10 インスメッド インコーポレイテッド 細菌感染症を治療するための組成物及び方法
GB201600290D0 (en) 2016-01-07 2016-02-24 Fujifilm Diosynth Biotechnologies Uk Ltd Process
US10183108B2 (en) 2016-02-04 2019-01-22 Pall Corporation Inline diafiltration with multi-channel pump
US20190029970A1 (en) 2017-07-31 2019-01-31 The Chinese University Of Hong Kong Fatty acid conjugated nanoparticles and uses thereof
US11571386B2 (en) 2018-03-30 2023-02-07 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
US20210113467A1 (en) 2018-05-02 2021-04-22 Robert Worsham Methods for the manufacture of liposomal drug formulations
EP3980023A4 (en) 2019-06-06 2023-08-02 Board of Regents, The University of Texas System LIPIDAN NOPARTICLES WITH PHARMACEUTICAL AND/OR NUTRACEUTICAL ACTIVE INGREDIENTS AND METHODS THEREOF
EP4351730A1 (en) 2021-06-09 2024-04-17 Insmed Incorporated In vitro release assay methods for liposomal aminoglycoside formulations

Also Published As

Publication number Publication date
US9895385B2 (en) 2018-02-20
EP3142643A4 (en) 2018-01-10
KR20170005104A (ko) 2017-01-11
CY1122129T1 (el) 2020-11-25
CY1123411T1 (el) 2021-12-31
US20200268781A1 (en) 2020-08-27
EP3142643A1 (en) 2017-03-22
KR20240018675A (ko) 2024-02-13
PL3466432T3 (pl) 2021-02-08
US10251900B2 (en) 2019-04-09
EP4122470A1 (en) 2023-01-25
US11446318B2 (en) 2022-09-20
KR20230015496A (ko) 2023-01-31
JP6892529B2 (ja) 2021-06-23
US20230037417A1 (en) 2023-02-09
EP3142643B1 (en) 2019-07-10
MX2016014921A (es) 2017-07-28
EP3466432B1 (en) 2020-07-08
JP2021143187A (ja) 2021-09-24
US10238675B2 (en) 2019-03-26
ME03536B (me) 2020-04-20
HUE051440T2 (hu) 2021-03-01
US10588918B2 (en) 2020-03-17
DK3142643T3 (da) 2019-10-14
KR102489036B1 (ko) 2023-01-13
BR112016026699A2 (pt) 2017-08-15
EP3766501A1 (en) 2021-01-20
PT3142643T (pt) 2019-10-28
US20190160086A1 (en) 2019-05-30
US10398719B2 (en) 2019-09-03
US12016873B2 (en) 2024-06-25
AU2020204530A1 (en) 2020-07-30
BR112016026699B1 (pt) 2022-09-13
DK3466432T3 (da) 2020-09-28
SI3142643T1 (sl) 2019-11-29
US20240366643A1 (en) 2024-11-07
CA2949078A1 (en) 2015-11-19
JP7212717B2 (ja) 2023-01-25
EP4393491A3 (en) 2024-07-24
KR102657132B1 (ko) 2024-04-12
JP2017515913A (ja) 2017-06-15
SI3466432T1 (sl) 2020-11-30
BR112016026699A8 (pt) 2021-06-29
AU2015258947B2 (en) 2020-04-09
ES2926985T3 (es) 2022-10-31
US11395830B2 (en) 2022-07-26
EP4122470B1 (en) 2024-03-20
PL3142643T3 (pl) 2019-12-31
LT3142643T (lt) 2019-10-25
NZ726256A (en) 2022-11-25
US20180311267A1 (en) 2018-11-01
EP4393491A2 (en) 2024-07-03
US20150328244A1 (en) 2015-11-19
US20230330119A1 (en) 2023-10-19
US20170360816A1 (en) 2017-12-21
US20210228606A1 (en) 2021-07-29
CN106535877A (zh) 2017-03-22
PT3466432T (pt) 2020-10-08
US10751355B2 (en) 2020-08-25
KR20220136448A (ko) 2022-10-07
KR102447412B1 (ko) 2022-09-23
EP3766501B1 (en) 2022-07-06
CA2949078C (en) 2022-09-20
ES2981634T3 (es) 2024-10-09
JP2020055877A (ja) 2020-04-09
JP6646653B2 (ja) 2020-02-14
ES2755941T3 (es) 2020-04-24
US20200345754A1 (en) 2020-11-05
US20200009171A1 (en) 2020-01-09
AU2020204530B2 (en) 2022-06-23
LT3466432T (lt) 2020-12-28
US20220395524A1 (en) 2022-12-15
WO2015175939A1 (en) 2015-11-19
US20190216834A1 (en) 2019-07-18
JP2023033417A (ja) 2023-03-10
HRP20191805T1 (hr) 2019-12-27
EP3466432A1 (en) 2019-04-10
AU2015258947A1 (en) 2017-01-12
US20180185401A1 (en) 2018-07-05
MX2020010726A (es) 2021-07-27
US10828314B2 (en) 2020-11-10
ES2820226T3 (es) 2021-04-20

Similar Documents

Publication Publication Date Title
PL3142643T3 (pl) Sposoby leczenia zakażeń płuc prątkami niegruźliczymi
PL3785717T3 (pl) Sposoby leczenia infekcji coronaviridae
GB201406151D0 (en) Method
EP3229808A4 (en) Methods for treating fungal infections
GB201414496D0 (en) Method
EP3188722A4 (en) Methods for treating protozoan infections
SG10201503996XA (en) Method for processing local information
GB201403470D0 (en) Method
IL249616A0 (en) Methods for treating inflammation
GB2531269B (en) Tape application method
PT3160263T (pt) Composições para prevenção de infeções
TH1501004125A (th) สารประกอบและวิธีการสำหรับการรักษาการติดเชื้อแบคทีเรีย
AU2014903503A0 (en) Methods For Treating Protozoan Infections
AU2014902467A0 (en) Methods For Treating Protozoan Infections
GB201419758D0 (en) Alice method
TH1601000110A (th) อุปกรณ์ทำให้สมดุล, อุปกรณ์ทำให้สม่ำเสมอ และวิธีการสำหรับใช้สิ่งดังกล่าว
GB201410316D0 (en) Recording method
GB201407948D0 (en) Method
GB201407815D0 (en) Method
GB201407809D0 (en) Method
GB201406509D0 (en) Method
GB201406398D0 (en) Method
GB201406399D0 (en) Method
GB201406147D0 (en) Method
GB201406178D0 (en) Method